Scribe Therapeutics Inc. Common Stock (SCTX)
Stock · NASDAQ · Health Care
$20.08as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About SCTX
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 82
- Website
- www.scribetx.com
Fundamentals
- 1-day range
- $17$19.36
- Market cap
- $411.18M
- P/E (trailing)
- —
- P/E (forward)
- -4.75
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- -2.64
- Avg. volume
- 328.8K
52-week range
$16.49$39.6
Next earnings: November 11, 2026 · EPS estimate $-1.03
Forecasts
4 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$60
+198.8%
Median
$59
+193.8%
Low
$50
+149.0%
Scribe Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SCTXScribe Therapeutics Inc. Common Stock$20.08▼ 3.09%Market cap $411.18MP/E —$16.49$39.6
- CCCCC4 Therapeutics Inc. Common Stock$2.77▼ 0.54%Market cap $402.46MP/E —$1.69$5.17
- OCGNOcugen Inc. Common Stock$0.78▼ 4.18%Market cap $420.50MP/E —$0.785$2.73
- STROSutro Biopharma Inc. Common Stock$10.94▼ 4.54%Market cap $400.18MP/E —$7.15$43.85
- XFORX4 Pharmaceuticals Inc. Common Stock$2.59▼ 1.89%Market cap $393.31MP/E 3.24$2.43$4.83
- FENCFennec Pharmaceuticals Inc. Common Stock$9.98▼ 3.57%Market cap $378.17MP/E —$5.65$13.25
- CABACabaletta Bio Inc. Common Stock$1.41▼ 9.03%Market cap $450.03MP/E —$1.51$4.23
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SCTX Scribe Therapeutics Inc. Common Stock | $411.18M | — | $20.08 | ▼ 3.09% | $16.49$39.6 |
| CCCC C4 Therapeutics Inc. Common Stock | $402.46M | — | $2.77 | ▼ 0.54% | $1.69$5.17 |
| OCGN Ocugen Inc. Common Stock | $420.50M | — | $0.78 | ▼ 4.18% | $0.785$2.73 |
| STRO Sutro Biopharma Inc. Common Stock | $400.18M | — | $10.94 | ▼ 4.54% | $7.15$43.85 |
| XFOR X4 Pharmaceuticals Inc. Common Stock | $393.31M | 3.24 | $2.59 | ▼ 1.89% | $2.43$4.83 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $9.98 | ▼ 3.57% | $5.65$13.25 |
| CABA Cabaletta Bio Inc. Common Stock | $450.03M | — | $1.41 | ▼ 9.03% | $1.51$4.23 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech NamesYahoo · 9/22/2026
- Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest BetsBenzinga · 9/22/2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga · 9/22/2026
- Gene-Editing Powerhouse And Its Rivals Surge Toward A BreakoutYahoo · 9/17/2026
Insider Activity
Insider Actions →Acquired
5.85M
Disposed
20.49M
- Aghazadeh Behzad · July 28, 2026 · Buy7.9K @ $18.25
- ORBIMED ADVISORS LLC · July 27, 2026 · Conversion2.07M
- ORBIMED ADVISORS LLC · July 27, 2026 · Buy1.00M @ $15
- ORBIMED ADVISORS LLC · July 27, 2026 · Conversion348.8K
- Jennifer A. Doudna · July 27, 2026 · Conversion74.1K
- Jennifer A. Doudna · July 27, 2026 · Conversion12.5K
- Carl L. Gordon · July 27, 2026 · Conversion2.07M
- Carl L. Gordon · July 27, 2026 · Buy1.00M @ $15
- Carl L. Gordon · July 27, 2026 · Conversion348.8K
- AH Bio Fund II, L.P. · July 27, 2026 · Conversion4.13M
- AH Bio Fund II, L.P. · July 27, 2026 · Conversion12.15M
- AH Bio Fund II, L.P. · July 27, 2026 · Buy333.3K @ $15
- AH Bio Fund II, L.P. · July 27, 2026 · Conversion697.6K
- AH Bio Fund II, L.P. · July 27, 2026 · Conversion2.05M
- Aghazadeh Behzad · July 24, 2026 · Buy50.0K @ $22.31
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings
ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings. ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.